■近年来出现了对他汀类药物相关神经认知障碍的担忧。然而,先前的研究报告了不一致的结果.我们使用FDA不良事件报告系统(FAERS)评估了他汀类药物与神经认知障碍之间的关联。
■2004年至2022年的数据是从FAERS数据库获得的。在重复和药品名称标准化之后,我们提取了他汀类药物报告的神经认知障碍事件(NCDE)病例作为可疑药物.使用报告比值比(ROR)和信息成分评估他汀类药物与NCDE之间的显着关联。
■总共,确定了6,959例以他汀类药物为主要可疑药物的NCDE病例。在普伐他汀中检测到信号(ROR,1.49;95%CI:1.32-1.67),阿托伐他汀(ROR,1.39;95%CI:1.34-1.44),和辛伐他汀(ROR,1.31;95%CI:1.25-1.38)。年龄分层分析表明:(1)在65岁及以上的人群中,检测到阿托伐他汀的信号,辛伐他汀,瑞舒伐他汀,普伐他汀,洛伐他汀,氟伐他汀,和匹伐他汀;(2)在65岁以下的人群中,检测到阿托伐他汀的信号,辛伐他汀,瑞舒伐他汀,普伐他汀,还有洛伐他汀.
■这项研究表明,NCDE与他汀类药物之间存在显着关联,包括阿托伐他汀,辛伐他汀,还有普伐他汀.关联的强度随着年龄的增长而增加。
随着近年来他汀类药物在全球范围内的广泛使用,一些患者报告他汀类药物导致认知障碍。研究人员对这个问题进行了研究;然而,结果不一致。一些人认为他汀类药物对认知功能没有影响,虽然其他人认为它们是有益的,其他人认为它们有负面影响。为了进一步调查这个问题,我们分析了FDA不良事件报告系统的数据,收集全世界人们报告的药物不良反应,评估他汀类药物与认知障碍之间的关系。我们的研究结果表明,一些他汀类药物与认知障碍有关。因此,当服用他汀类药物的患者发生认知变化时,他们应该认真对待。
UNASSIGNED: Concerns regarding statin-related neurocognitive disorders have emerged in recent years. However, previous studies have reported inconsistent results. We evaluated the association between statins and neurocognitive disorders using the FDA Adverse Event Reporting System (FAERS).
UNASSIGNED: Data from 2004 to 2022 were obtained from the FAERS database. After deduplication and standardization of drug names, we extracted neurocognitive disorder event (NCDE) cases reported with statins as the suspected drugs. The significant association between statins and NCDE was evaluated using the reporting odds ratio (ROR) and information component.
UNASSIGNED: In total, 6,959 NCDE cases with statins as the primary suspected drugs were identified. Signals were detected in pravastatin (ROR, 1.49; 95% CI: 1.32-1.67), atorvastatin (ROR, 1.39; 95% CI: 1.34-1.44), and simvastatin (ROR, 1.31; 95% CI: 1.25-1.38). Age-stratified analysis showed that (1) in the population aged 65 years and older, signals were detected for atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, and pitavastatin; and (2) in populations under 65 years of age, signals were detected for atorvastatin, simvastatin, rosuvastatin, pravastatin, and lovastatin.
UNASSIGNED: This study suggests a significant association between the NCDE and statins, including atorvastatin, simvastatin, and pravastatin. The intensity of the association increased with age.
With the extensive use of statins worldwide in recent years, some patients have reported that statins lead to cognitive impairment. Researchers have conducted studies on this issue; however, the results have been inconsistent. Some believe that statins have no impact on cognitive function, while others believe they are beneficial, and others believe they have negative effects.To further investigate this issue, we analyzed data from the FDA adverse event reporting system, which collects adverse drug reactions reported by people worldwide, to evaluate the association between statins and cognitive impairment. Our findings suggest that some statins are associated with cognitive impairment. Therefore, when cognitive changes occur in patients taking statins, they should be taken seriously.